Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

Por Jeong, Seongwook, Woo, Margaret M., Flockhart, David A., Desta, Zeruesenay
Publicado em 2009

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors

Por Savelieva, Marina, Woo, Margaret M., Schran, Horst, Mu, Song, Nedelman, Jerry, Capdeville, Renaud
Publicado no Eur J Clin Pharmacol (2015)

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

Por Shapiro, Geoffrey I., Frank, Richard, Dandamudi, Uday B., Hengelage, Thomas, Zhao, Lily, Gazi, Lucien, Porro, Maria Grazia, Woo, Margaret M., Lewis, Lionel D.
Publicado no Cancer Chemother Pharmacol (2011)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Por Hamberg, Paul, Woo, Margaret M., Chen, Lin-Chi, Verweij, Jaap, Porro, Maria Grazia, Zhao, Lily, Li, Wenkui, van der Biessen, Diane, Sharma, Sunil, Hengelage, Thomas, de Jonge, Maja
Publicado em 2011